Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.
Bionano Genomics, Inc. (NASDAQ: BNGO) regularly issues news and updates about its genome analysis technologies, financial results and scientific collaborations. The company describes itself as a provider of optical genome mapping (OGM) solutions, diagnostic services and software that support research and clinical research applications in areas such as inherited disease, reproductive disorders, hematologic malignancies, solid tumors and rare diseases.
On this page, readers can follow Bionano’s announcements about quarterly and annual financial results, capital markets transactions, and strategic shifts in its business model. Recent press releases have discussed the company’s focus on routine users of its OGM solutions, trends in consumables and software utilization, and public offerings of common stock and warrants disclosed through SEC filings and corresponding news releases.
Bionano’s news flow also highlights scientific and clinical research progress involving OGM. The company frequently reports on studies presented at major conferences such as the American Society of Human Genetics (ASHG) and the Association for Molecular Pathology (AMP), where researchers have described OGM’s use in detecting structural variants across a range of genetic conditions. In addition, Bionano has drawn attention to peer-reviewed publications, including work from The University of Texas MD Anderson Cancer Center comparing OGM with targeted RNA-sequencing in acute leukemia.
Updates from Bionano Laboratories, the company’s CLIA-certified laboratory business, cover developments in OGM-based laboratory developed tests and reimbursement, including Category I CPT codes 81195 and 81354 for OGM applications in hematologic malignancies and constitutional genetic disease. Investors and researchers can use this news page to review BNGO’s historical and ongoing disclosures about its technology platforms, research collaborations, reimbursement milestones and financial performance.
Bionano Genomics (BNGO) has announced the adoption of its Saphyr system for optical genome mapping (OGM) by two major UK National Health Service (NHS) laboratories: King’s College Hospital and the NHS Regional Genetics Laboratory in Belfast. These institutions will use Saphyr to assess genomes of patients with hematological malignancies, among other genetic diseases. CEO Erik Holmlin emphasized that this shift towards OGM represents a modernization of cytogenetic workflows, potentially accelerating data generation and enhancing patient care outcomes.
Bionano Genomics announced a new IRB-approved preclinical evaluation study using optical genome mapping (OGM) in partnership with the Foundation for Embryonic Competence (FEC) to improve IVF outcomes. The study will analyze genomes of couples with recurrent pregnancy loss or implantation failure to identify structural rearrangements that traditional methods may miss. OGM's high resolution aims to enhance preimplantation testing, potentially leading to healthier pregnancies. CEO Erik Holmlin emphasized the growth of OGM applications to support couples facing genetic challenges.
Bionano Genomics announced its largest presence at the 2021 ACMG Annual Meeting, showcasing 16 presentations related to its technology across key genetic markets. The event, held virtually from April 13-16, 2021, highlighted advancements in prenatal, postnatal, blood cancers, and solid tumors. CEO Erik Holmlin expressed pride in the extensive representation of Bionano data, emphasizing its growing significance in the medical genetics community and potential to overcome barriers in the US market.
Bionano Genomics (BNGO) announced that it will present multiple studies on structural variant detection using its optical genome mapping technology at the American Association for Cancer Research (AACR) Annual Meeting 2021. The event will take place virtually from April 10-15, 2021. Notable presentations include a Spotlight Presentation highlighting the technology's application in cancer research and a study discussing drug sensitivities in leukemias. Bionano's Saphyr system supports genetic research and diagnostic testing for neurodevelopmental disorders.
Bionano Genomics has announced the adoption of the Saphyr system for optical genome mapping by Indalo Bio in South Africa, representing the first use of this technology on the continent. Indalo Bio aims to develop assays for analyzing cancer genomes in patients with hematological malignancies and solid tumors. Jo-Ann Kotze, Head of Genetics at Indalo Bio, expressed confidence in OGM's potential to enhance cytogenetic analysis. CEO Erik Holmlin emphasized the importance of expanding access to advanced genetic technologies, particularly in Africa, which could improve patient outcomes globally.
Bionano Genomics (BNGO) recently published a study in the journal Genes detailing the effectiveness of optical genome mapping (OGM) in prenatal genetic testing. The study highlights OGM's capacity to detect all types of structural variants (SVs), positioning it as a potential new standard in prenatal analysis. Notable findings include the identification of genetic disorders like trisomy 21 and DiGeorge syndrome. The research emphasizes OGM's cost-effectiveness and quick turnaround time, suggesting it could enhance prenatal testing workflows significantly.
Bionano Genomics (BNGO) reported its financial results for Q4 2020, highlighting a revenue increase of 43% to $4 million compared to Q4 2019, primarily due to growth in service revenue from Lineagen. However, total revenue for 2020 decreased by $1.6 million to $8.5 million, impacted by COVID-19. The company raised approximately $335 million in early 2021, strengthening its balance sheet. They aim to enhance the adoption of their Saphyr® system in clinical testing and have ambitious milestones planned for 2021, including the expansion of clinical assays.
Bionano Genomics has announced its participation in two virtual investor conferences. Management will present at the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, at 11:20 AM ET. Additionally, presentations will be available at the Maxim Group's Emerging Growth Conference from March 17-19, 2021. Webcasts will be accessible on Bionano's website for 30 days post-event.
Bionano Genomics (NASDAQ: BNGO) presented virtually at the H.C. Wainwright Global Life Sciences Conference held on March 9-10, 2021. CEO Dr. Erik Holmlin's presentation is available on-demand on the conference portal and Bionano's investor page for 30 days post-event. Bionano specializes in genome analysis with its Saphyr system, designed for structural variation detection. This platform enables researchers to enhance diagnostics and therapeutic targets. Lineagen, a Bionano subsidiary, has provided over 65,000 genetic tests for neurodevelopmental disorders, including ASD.
Bionano Genomics (BNGO) will host a conference call and webcast on March 23, 2021, at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end financial results for 2020. The company will also highlight recent corporate advancements. Participants can join the call by dialing the provided toll-free or international numbers. Bionano provides genome analysis tools via its Saphyr system, aimed at enhancing genetic research and diagnostics.